Jinlong Liu,Xuejun Zhang,Shuguang Yang,Zhao Zhang,Qiuju Yue,Xiaodong Liu. Study on the protein expression and amplification of HER2 gene in gastric cancer. Oncol Transl Med, 2014, 13: 273-279. |
Study on the protein expression and amplification of HER2 gene in gastric cancer |
|
View Full Text View/Add Comment Download reader |
KeyWord:survivin; pancreatic cancer; meta-analysis |
Author Name | Affiliation | Jinlong Liu | Department of General Surgery 1, The Affiliated Hospital of Chengde Medical College, Chengde 067000, China | Xuejun Zhang | Department of General Surgery 1, The Affiliated Hospital of Chengde Medical College, Chengde 067001, China | Shuguang Yang | Department of General Surgery 1, The Affiliated Hospital of Chengde Medical College, Chengde 067002, China | Zhao Zhang | Department of General Surgery 1, The Affiliated Hospital of Chengde Medical College, Chengde 067003, China | Qiuju Yue | Department of General Surgery 1, The Affiliated Hospital of Chengde Medical College, Chengde 067004, China | Xiaodong Liu | Department of General Surgery 1, The Affiliated Hospital of Chengde Medical College, Chengde 067005, China |
|
Hits: 7182 |
Download times: 8219 |
Abstract: |
Objective: The aim of the study was to conduct a systematic review of the literature evaluating survivin expression in pancreatic carcinoma as a prognostic indicator. Methods: The relevant literatures were searched using PubMed, EMBASE, and Chinese Biomedicine Databases. A meta-analysis of the association between survivin expression and overall survival in patients with pancreatic cancer was performed. Studies were pooled and summary hazard ratios (HRs) were calculated. Subgroup analysis according to the location of survivin expression was also performed. Results: Seven eligible studies with a total of 448 patients were included in this study. Combined HR suggested that survivin expression had an unfavorable impact on survival of pancreatic cancer patients (HR = 1.65, 95% CI: 1.02–2.68). When stratified according to the location of survivin expression, the combined HR showed that expression in the cytoplasm was significantly associated with poor prognosis of pancreatic cancer patients (HR = 2.09, 95% CI: 1.29–3.40). In contrast, survivin expression in the nucleus was not significantly associated with poor prognosis (HR = 0.83, 95% CI: 0.24–2.81), and the heterogeneity was highly significant (I2 = 87.2%, P = 0.005). Conclusion: Survivin expression was associated with a poor prognosis in patients with pancreatic cancer. Cytoplasmic expression of survivin may be a prognostic factor for pancreatic cancer patients. Based on the current obtained data, there was no evidence that survivin expression in the nucleus had a significant impact on patients’ overall survival. |
Close |
|
|
|